| What Is endoscopic biopsy surveillance? |
|
Bani-Hani K, Martin IG, Hardie LJ, Mapstone N, Briggs JA, Forman D, Wild CP. Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma. Journal of the National Cancer Institute 2000; 92(16):1316-21. |
|
Begg CB, Cramer LD, Hoskins WJ, Brennan MF. Impact of hospital volume on operative mortality for major cancer surgery. Jama 1998; 280(20):1747-51. |
|
Birkmeyer JD, Siewers AE, Finlayson EV, Stukel TA, Lucas FL, Batista I, Welch HG, Wennberg DE. Hospital volume and surgical mortality in the United States. The New England Journal of Medicine 2002; 346(15):1128-37. |
|
Byrne JP, Armstrong GR, Attwood SE. Restoration of the normal squamous lining in Barrett's esophagus by argon beam plasma coagulation [see comments]. American Journal Of Gastroenterology 1998; 93(10):1810-5. |
|
Cameron AJ, Carpenter HA. Barrett's esophagus, high-grade dysplasia, and early adenocarcinoma: a pathological study. American Journal of Gastroenterology 1997; 92(4):586-91. |
|
Cameron AJ. Barrett's esophagus: does the incidence of adenocarcinoma matter? [editorial; comment] [see comments]. American Journal Of Gastroenterology 1997; 92(2):193-4. |
|
Cameron AJ. Management of Barrett's esophagus. Mayo Clinic Proceedings 1998; 73(5):457-61. |
|
Canto MI, Setrakian S, Willis J, Chak A, Petras R, Powe NR, Sivak MV. Methylene blue-directed biopsies improve detection of intestinal metaplasia and dysplasia in Barrett's esophagus. Gastrointestinal Endoscopy 2000; 51(5):560-8. |
|
Canto MI. Vital staining and Barrett's esophagus. Gastrointestinal Endoscopy 1999; 49(3 Pt 2):S12-6. |
|
Conio M, Cameron AJ, Romero Y, Branch CD, Schleck CD, Burgart LJ, Zinsmeister AR, Melton LJ, Locke GR. Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota. Gut 2001; 48(3):304-9. |
|
Corley DA, Levin TR, Habel LA, Weiss NS, Buffler PA. Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology 2002; 122(3):633-40. |
|
Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. American Journal of Gastroenterology 1997; 92(2):212-5. |
|
Dulai GS, Guha S, Kahn KL, Gornbein J, Weinstein WM. Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: a systematic review. Gastroenterology 2002; 122(1):26-33. |
| Dulai GS, Jensen DM,
Cortina G, Fontana L, Ippoliti A. Randomized trial of argon plasma
coagulation vs. multipolar electrocoagulation for ablation of
Barrett's esophagus. Gastrointestinal Endoscopy 2005;61:232-40. |
|
Edwards M, Gable D, Lentsch A. The rationale for esophagectomy as the optimal therapy for Barrett's esophagus with high-grade dysplasia. Annals of Surgery 1996; 223:585-591. |
| Eisen G. Ablation
therapy for Barrett's esophagus. Gastrointestinal Endoscopy 2003;
58:760-8. |
|
Falk GW, Rice TW, Goldblum JR, Richter JE. Jumbo biopsy forceps protocol still misses unsuspected cancer in Barrett's esophagus with high-grade dysplasia. Gastrointestinal Endoscopy 1999; 49(2):170-6. |
|
Farrow DC, Vaughan TL. Determinants of survival following the diagnosis of esophageal adenocarcinoma (United States). Cancer Causes and Control 1996; 7(3):322-7. |
|
Fennerty MB, Sampliner RE, Way D, Riddell R, Steinbronn K, Garewal HS. Discordance between flow cytometric abnormalities and dysplasia in Barrett's esophagus. Gastroenterology 1989; 97(4):815-20. |
|
Fennerty MB. Perspectives on endoscopic eradication of Barrett's esophagus: who are appropriate candidates and what is the best method? Gastrointest Endosc 1999; 49(3 Pt 2):S24-8. |
|
Galipeau PC, Cowan DS, Sanchez CA, Barrett MT, Emond MJ, Levine DS, Rabinovitch PS, Reid BJ. 17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus. Proceedings of the National Academy of Sciences of the United States of America 1996; 93(14):7081-4. |
|
Galipeau PC, Prevo LJ, Sanchez CA, Longton GM, Reid BJ. Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue. Journal of the National Cancer Institute 1999; 91(24):2087-95. |
|
Gangarosa L, Halter S, Mertz H. Methylene blue staining and endoscopic ultrasound evaluation of Barrett's esophagus with low-grade dysplasia. Digestive Disease Science 2000; 45(2):225-229. |
| Ganz RA, Utley DS,
Stern RA, Jackson J, Batts KP, Termin P. Complete
ablation of esophageal epithelium with a balloon-based bipolar
electrode: a phased evaluation in the porcine and in the human
esophagus. Gastrointestinal Endoscopy 2004; 60:1002-10. |
|
Geisinger KR, Teot LA, Richter JE. A comparative cytopathologic and histologic study of atypia, dysplasia, and adenocarcinoma in Barrett's esophagus. Cancer 1992; 69(1):8-16. |
|
Guelrud M, Herrera I, Essenfeld H, Castro J. Enhanced magnification endoscopy: a new technique to identify specialized intestinal metaplasia in Barrett's esophagus. Gastrointestinal Endoscopy 2001; 53(6):559-65. |
|
Haag S, Nandurkar S, Talley NJ. Regression of Barrett's esophagus: the role of acid suppression, surgery, and ablative methods. Gastrointest Endosc 1999; 50(2):229-40. |
|
Hameeteman W, Tytgat GN, Houthoff HJ, van den Tweel JG. Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology 1989; 96(5 Pt 1):1249-56. |
|
Heitmiller RF, Redmond M, Hamilton SR. Barrett's esophagus with high-grade dysplasia. An indication for prophylactic esophagectomy. Annals Of Surgery 1996; 224(1):66-71. |
| Johnston MH, Eastone
JA, Horwhat JD, Cartledge J, Mathews JS, Foggy JR. Cryoablation of
Barrett's esophagus: a pilot study. Gastrointestinal Endoscopy
2005; 62:842-8. |
|
Katz D, Rothstein R, Schned A, Dunn J, Seaver K, Antonioli D. The development of dysplasia and adenocarcinoma during endoscopic surveillance of Barrett's esophagus. American Journal Of Gastroenterology 1998; 93(4):536-41. |
|
Krishnadath KK, Reid BJ, Wang KK. Biomarkers in Barrett esophagus. Mayo Clinic Proceedings 2001; 76(4):438-46. |
|
Krishnadath KK, Wang KK, Taniguchi K, Sebo TJ, Buttar NS, Anderson MA, Lutzke LS, Liu W. Persistent genetic abnormalities in Barrett's esophagus after photodynamic therapy. Gastroenterology 2000; 119(3):624-30. |
|
Levine DS, Blount PL, Rudolph RE, Reid BJ. Safety of a systematic biopsy protocol in patients with Barrett's esophagus. American Journal of Gastroenterology 2000; 95:1152-1157. |
|
Levine DS, Haggitt RC, Blount PL, Rabinovitch PS, Rusch VW, Reid BJ. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. Gastroenterology 1993; 105(1):40-50. |
|
Levine DS, Reid BJ. Endoscopic Diagnosis of Esophageal Neoplasms. Gastrointestinal Tumors 1992; 2(3):395-413. |
|
Levine DS. Management of dysplasia in the columnar-lined esophagus. Gastroenterology Clinics of North America 1997; 26(3):613-34. |
|
McArdle JE, Lewin KJ, Randall G, Weinstein W. Distribution of dysplasias and early invasive carcinoma in Barrett's esophagus [see comments]. Human Pathology 1992; 23(5):479-82. |
|
Miros M, Kerlin P, Walker N. Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus. Gut 1991; 32(12):1441-6. |
|
O'Connor JB, Falk GW, Richter JE. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry. American Journal of Gastroenterology 1999; 94(8):2037-42. |
|
Ovaska J, Miettinen M, Kivilaakso E. Adenocarcinoma arising in Barrett's esophagus. Dig Dis Sci 1989; 34(9):1336-9. |
| Overholt BF, Lightdale
CJ, Wang KK, Canto MI, Burdick S, Haggitt RC, Bronner MP, Taylor
SL, Grace MG, Depot M; International Photodynamic Group for
High-Grade Dsyplasia in Barrett's Esophagus. Phtodynamic therapy
with porfimer sodium for ablation of high-grade dysplasia in
Barrett's esophagus; international, partially blinded, randomized
phase III trial. Gastrointestinal Endoscopy 2005; 62: 488-98. |
| Overholt BF, Panjehpour
M, Halberg DL. Photodynamic therapy for Barrett's esophagus with
dysplasia and /or early stage cancer. Gastrointestinal Endoscopy,
2003, 58(2); 183-8. |
|
Overholt BF, Panjehpour M, Haydek JM. Photodynamic therapy for Barrett's esophagus: follow-up in 100 patients. Gastrointestinal Endoscopy 1999; 49(1):1-7. |
|
Paraf F, Fljou JF, Pignon JP, Fkt F, Potet F. Surgical pathology of adenocarcinoma arising in Barrett's esophagus. Analysis of 67 cases. American Journal Of Surgical Pathology 1995; 19(2):183-91. |
|
Patti MG, Corvera CU, Glasgow RE, Way LW. A hospital's annual rate of esophagectomy influences the operative mortality rate. J Gastrointest Surg 1998; 2(2):186-92. |
|
Peters JH, Clark GW, Ireland AP, Chandrasoma P, Smyrk TC, DeMeester TR. Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and nonsurveyed patients. J Thorac Cardiovasc Surg 1994; 108(5):813-21; discussion 821-2. |
| Pech O, Gossner L, May
A, Rabenstein T, Vieth M, Stolte M, Berres M, Ell C. Long-term
results of photodynamic therapy with 5-aminolevulinic acid for
superficial Barrett's cancer and high-grade intraepithelial
neoplasia. Gastrointestinal Endoscopy 2005; 62 (1): 24-30. |
|
Prevo LJ, Sanchez CA, Galipeau PC, Reid BJ. p53-mutant clones and field effects in Barrett's esophagus. Cancer Research 1999; 59(19):4784-7. |
|
Provenzale D, Schmitt C, Wong JB. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol 1999; 94(8):2043-53. |
|
Reid BJ, Blount PL, Feng Z, Levine DS. Optimizing endoscopic biopsy detection of early cancers in Barrett's high-grade dysplasia. The American Journal of Gastroenterology 2000; 95(11):3089-96. |
|
Reid BJ, Blount PL, Rubin CE, Levine DS, Haggitt RC, Rabinovitch PS. Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort. Gastroenterology 1992; 102(4 Pt 1):1212-9. |
|
Reid BJ, Levine DS, Longton G, Blount PL, Rabinovitch PS. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. American Journal of Gastroenterology 2000; 95(7):1669-76. |
|
Reid BJ, Prevo LJ, Galipeau PC, Sanchez CA, Longton G, Levine DS, Blount PL, Rabinovitch PS. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. The American Journal of Gastroenterology 2001; 96(10):2839-48. |
|
Reid BJ, Weinstein WM, Lewin KJ, Haggitt RC, VanDeventer G, DenBesten L, Rubin CE. Endoscopic biopsy can detect high-grade dysplasia or early adenocarcinoma in Barrett's esophagus without grossly recognizable neoplastic lesions. Gastroenterology 1988; 94(1):81-90. |
|
Robertson CS, Mayberry JF, Nicholson DA, James PD, Atkinson M. Value of endoscopic surveillance in the detection of neoplastic change in Barrett's oesophagus. Br J Surg 1988; 75(8):760-3. |
|
Rusch VW, Levine DS, Haggitt R, Reid BJ. The management of high grade dysplasia and early cancer in Barrett's esophagus. A multidisciplinary problem. Cancer 1994; 74(4):1225-9. |
|
Sampliner RE, . Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. The American Journal of Gastroenterology 2002; 97(8):1888-95. |
|
Sampliner RE. Ablation of Barrett's mucosa. Gastroenterologist 1997; 5(3):185-8. |
|
Sampliner RE. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1998; 93(7):1028-32. |
|
Schnell TG, Sontag SJ, Chejfec G, Aranha G, Metz A, O_Connell S, Seidel UJ, Sonnenberg A. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology 2001; 120(7):1607-19. |
|
Selvasekar CR, Birbeck N, McMillan T, Wainwright M, Walker SJ. Photodynamic therapy and the alimentary tract. Alimentary Pharmacology & Therapeutics 2001; 15(7):899-915. |
|
Sharma P, Bhattacharyya A, Garewal HS, Sampliner RE. Durability of new squamous epithelium after endoscopic reversal of Barrett's esophagus. Gastrointest Endosc 1999; 50(2):159-64. |
|
Sharma P, Topalovski M, Mayo MS, Weston AP. Methylene blue chromoendoscopy for detection of short-segment Barrett's esophagus. Gastrointestinal Endoscopy 2001; 54(3):289-93. |
|
Spechler SJ, Lee E, Ahnen D, Goyal RK, Hirano I, Ramirez F, Raufman JP, Sampliner R, Schnell T, Sontag S, Vlahcevic ZR, Young R, Williford W. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. Jama : the Journal of the American Medical Association 2001; 285(18):2331-8. |
|
Spechler SJ, Robbins AH, Rubins HB, Vincent ME, Heeren T, Doos WG, Colton T, Schimmel EM. Adenocarcinoma and Barrett's esophagus. An overrated risk? Gastroenterology 1984; 87(4):927-33. |
|
Spechler SJ. Clinical practice. Barrett's Esophagus. The New England Journal of Medicine 2002; 346(11):836-42. |
|
Stevens PD, Lightdale CJ, Green PH, Siegel LM, Garcia_Carrasquillo RJ, Rotterdam H. Combined magnification endoscopy with chromoendoscopy for the evaluation of Barrett's esophagus. Gastrointestinal Endoscopy 1994; 40(6):747-9. |
|
Teodori L, Gohde W, Persiani M, Ferrario F, Tirindelli Danesi D, Scarpignato C, Di Tondo U, Alo P, Capurso L. DNA/protein flow cytometry as a predictive marker of malignancy in dysplasia-free Barrett's esophagus: thirteen-year follow-up study on a cohort of patients. Cytometry 1998; 34(6):257-63. |
|
van den Boogert J, van Hillegersberg R, Siersema PD, de Bruin RW, Tilanus HW. Endoscopic ablation therapy for Barrett's esophagus with high-grade dysplasia: a review. American Journal of Gastroenterology 1999; 94(5):1153-60. |
|
van der Burgh A, Dees J, Hop WC, van Blankenstein M. Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. Gut 1996; 39(1):5-8. |
|
Van Laethem JL, Cremer M, Peny MO, Delhaye M, Devire J. Eradication of Barrett's mucosa with argon plasma coagulation and acid suppression: immediate and mid term results [see comments]. Gut 1998; 43(6):747-51. |
|
van Lieshout EM, Jansen JB, Peters WH. Biomarkers in Barrett's esophagus. Int J Oncol 1998; 13(4):855-64. |
|
van Sandick JW, van Lanschot JJ, Kuiken BW, Tytgat GN, Offerhaus GJ, Obertop H. Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma. Gut 1998; 43(2):216-22. |
|
Wang KK. Current status of photodynamic therapy of Barrett's esophagus. Gastrointest Endosc 1999; 49(3 Pt 2):S20-3. |
| Wang KK., Wongseesong
M, Buttar NS. American Gastroenterological Association medical
position statement: role of the gastroenterologist in the
management of esophageal carcinoma. Gastroenterology
2005;128:1468-70. |
| Wang TD, Van Dam J.
Optical biopsy; a new frontier in endoscopic detection and
diagnosis. Clinical Gasroenterology and Hepatology 2004;2:744-53. |
|
Weston AP, Banerjee SK, Sharma P, Tran TM, Richards R, Cherian R. p53 protein overexpression in low grade dysplasia (LGD) in Barrett's esophagus: immunohistochemical marker predictive of progression. The American Journal of Gastroenterology 2001; 96(5):1355-62. |
|
Wright TA. High-grade dysplasia in Barrett's oesophagus. British Journal Of Surgery 1997; 84(6):760-6. |
